Abstract
Importance Recent Alzheimer’s disease (AD) clinical trials have used Cerebrospinal fluid (CSF) biomarker levels for screening and enrollment. Preliminary evidence suggests Alzheimer’s Disease (AD) risk may be related to impaired renal function but the association of variation in levels of commonly used AD biomarkers with kidney function are unknown.
Objective To investigate the association between estimated glomerular filtration rate (eGFR), CSF levels of AD biomarkers: amyloid beta1–42 (Aβ42), Tau or phosphorylated Tau181 (pTau).
Design, Setting, and Participants We conducted an analysis using data from participants enrolled in two research protocols at the Goizueta Alzheimer’s Disease Research Center that had simultaneous measurements of serum creatinine at the time of their Cerebrospinal fluid (CSF) collection (N=973). The participants had a mean age of 66.52 years, 23.33% were African American, and 63% were women, with 42.46% having mild cognitive impairment (MCI). The estimated glomerular filtration rate (eGFR) was obtained from chronic kidney disease Epidemiology Collaboration. All participants had similar CSF collection procedures. Aβ42, Tau or pTau were measured on the Luminex ALZBIO platform. General linear models and individual data were used to assess relationships between biomarkers and eGFR.
Results Lower eGFR was associated with lower Aβ42/Tau ratio (slope= 0.033 units, p<0.0001) and Aβ42 (slope=0.75, p=0.002) and higher Tau (slope= -0.39, p<0.0001) and pTau (slope= -0.13, p=0.0002). Although these associations remained significant after adjusting for cognitive status, we observed interactions between MCI and eGFR. This interaction revealed that the impact of eGFR on AD biomarker levels was more robust in individuals with cognitive impairment (interaction MCI*GFR p-values were 0.005 for Ab42, 0.04 for tau and pTau, and 0.05 for the ratio).
Conclusion We found a significant association between eGFR with CSF AD-biomarkers that may differ by cognitive status. This suggests that kidney function should be considered both in the context of interpreting AD biomarkers as well as exploring potential systemic factors that may increase risk of AD. Future longitudinal studies need to further explore the impact of kidney function on the pathogenesis of AD and related Biomarkers.
Question Are Cerebrospinal Fluid (CSF)AD-biomarker measurements impacted by kidney function?
Findings In this analysis of data from 973 individuals who had both cerebrospinal fluid (CSF) AD-biomarkers (Aβ42, Tau, and pTau181) and kidney function measurements, there were significant associations between estimated glomerular filtration rate (eGFR) and measures of CSF AD-biomarkers. These associations were more pronounced in those with cognitive impairment.
Meaning Kidney function may have a significant impact on AD-biomarker measurements in the CSF, especially in those in the early symptomatic stages of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institute on Aging (NIA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Protocols were approved by the Emory IRB (Institutional Review Board) and each participant signed a written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding authors
